CHLORPHENIRAMINE MALEATE Drug Patent Profile
✉ Email this page to a colleague
When do Chlorpheniramine Maleate patents expire, and what generic alternatives are available?
Chlorpheniramine Maleate is a drug marketed by Aurolife Pharma Llc, Bel Mar, Elkins Sinn, Watson Labs, Pharm Assoc, Avanthi Inc, Anabolic, Bell Pharma, Impax Labs, Ivax Sub Teva Pharms, Kv Pharm, Lederle, Newtron Pharms, Panray, Pharmavite, Pharmeral, Pioneer Pharms, Purepac Pharm, Pvt Form, Roxane, Sun Pharm Industries, Vitarine, and West Ward. and is included in thirty NDAs.
The generic ingredient in CHLORPHENIRAMINE MALEATE is chlorpheniramine maleate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the chlorpheniramine maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Chlorpheniramine Maleate
A generic version of CHLORPHENIRAMINE MALEATE was approved as chlorpheniramine maleate by AVANTHI INC on May 13th, 2009.
Summary for CHLORPHENIRAMINE MALEATE
US Patents: | 0 |
Applicants: | 23 |
NDAs: | 30 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Clinical Trials: | 9 |
Patent Applications: | 2,749 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CHLORPHENIRAMINE MALEATE |
DailyMed Link: | CHLORPHENIRAMINE MALEATE at DailyMed |
Recent Clinical Trials for CHLORPHENIRAMINE MALEATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hospital CEMESA Cortés, San Pedro Sula, Honduras | Phase 2/Phase 3 |
Dr. Ferrer BioPharma | Phase 2/Phase 3 |
Marcos Sanchez-Gonzalez, MD, PhD | Phase 2/Phase 3 |
Pharmacology for CHLORPHENIRAMINE MALEATE
Drug Class | Histamine-1 Receptor Antagonist |
Mechanism of Action | Histamine H1 Receptor Antagonists |